Fig. 6: ProIFN improves radiation efficacy.
a, b C57BL/6 J mice were s.c. inoculated with 5 × 105 B16 tumor cells and i.p. treated with 1 nmol (8 mg/kg) of mProIFNa4-Fc on day 10, 13, and 16 (n = 9). Tumors were locally received a single 30-Gy dose on day 9. Tumor growth (a) and survival curve (b) were shown. c Western blot analysis of MMP-2 expression level from the culture supernatant of MDA-MB-231 cells. The experiment was repeated twice independently with similar results. d Flow cytometry analysis of MMP-14 expression level on MDA-MB-231 cells. e–g Human CD34 + hematopoietic stem cells transferred NSG-SGM3 mice were s.c. inoculated with 2 × 106 MDA-MB-231 tumor cells and i.p. treated with 10 mg/kg hProIFNa2b-Fc on day 18, 21, 24, 31, 40, and 47 (n = 9 animals for Ctrl, n = 10 animals for hProIFNa2b-Fc, n = 9 animals for IR, n = 8 animals for hProIFNa2b-Fc + IR). Tumors were locally received a single 12-Gy dose on day 17. Mice were euthanized on day 57. Lung metastasis percentage (e), liver metastasis percentage (f), and number of liver metastasis nodules were shown (g). Data are reported as mean ± s.e.m. Two-way ANOVA (a), the logrank test, (b) or two-tailed t-tests (g) were performed to calculate p-values. Source data are provided as a Source Data file.
